First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

$ 25.50

4.8
(680)
In stock
Description

The role of lipids in cancer progression and metastasis

First-in-human study of the safety, pharmacokinetics, and

Acetyl-CoA metabolism as a therapeutic target for cancer

PDF) Metabolic dysregulation and emerging therapeutical targets

PDF) First-in-human study of the safety, pharmacokinetics, and

Frontiers First-In-Human Study to Assess the Safety

PDF) Metabolic dysregulation and emerging therapeutical targets

FASCINATE Phase 2a Trial Evaluating TVB-2640 Shows Reduced Excess

Targeting fatty acid uptake and metabolism in cancer cells: A

Acetyl-CoA metabolism as a therapeutic target for cancer

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640

Suppressing fatty acid synthase by type I interferon and chemical

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Targeting fatty acid uptake and metabolism in cancer cells: A